Trials / Unknown
UnknownNCT05170542
The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.
A Single-arm, Phase II Study of Camrelizumab Combined With S-1 Maintenance After First-Line Induction Chemotherapy in Patients With HER2 Negative Advanced Gastric Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 42 (estimated)
- Sponsor
- Peking Union Medical College Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, We investigated the efficacy and safty of camrelizumab combined with S-1 maintenance after first-line induction chemotherapy for GC. Patients without progressive disease after 4-6 weeks of first-line chemotherapy with SOX will be treated with camrelizumab combined with S-1.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Camrelizumab+S-1 | Camrelizumab: intravenous drip, fixed dose 200 mg, D1, repeated once every 3 weeks. |
Timeline
- Start date
- 2021-12-24
- Primary completion
- 2025-12-24
- Completion
- 2026-01-24
- First posted
- 2021-12-28
- Last updated
- 2021-12-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05170542. Inclusion in this directory is not an endorsement.